Media , NEWS
2020.10.2
The research license agreement between Rebirthel and Otsuka Pharmaceutical was reported on Kyoto Shimbun (Japanese newspaper).
In the morning edition of Kyoto Shimbun on October 2nd, 2020 (Economy section, Page 11), the conclusion of the research license agreement between Rebirthel and Otsuka Pharmaceutical was reported.
Under this agreement, Otsuka Pharmaceutical will utilize Rebirthel’s patented technology for their development of T cell preparations. In addition, the agreement gives Otsuka Pharmaceutical the priority negotiation right for a commercial license.
Rebirthel has made the press release to announce this agreement on October 1st, 2020.